Loic Campion

List of Publications by Year
in descending order

147 papers	7,238 citations	61984 43 h-index	60623 81 g-index
163 all docs	163 docs citations	163 times ranked	9282 citing authors

#	Article	IF	Citations
1	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). Journal of Clinical Oncology, 2010, 28, 4630-4634.	1.6	383
2	Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6077-6084.	3.6	361
3	Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du MyÃ©lome. Journal of Clinical Oncology, 2008, 26, 4798-4805.	1.6	361
4	bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Research and Treatment, 2012, 131, 765-775.	2.5	308
5	Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography. Journal of Clinical Oncology, 2006, 24, 5366-5372.	1.6	290
6	Prognostic Significance of Copy-Number Alterations in Multiple Myeloma. Journal of Clinical Oncology, 2009, 27, 4585-4590.	1.6	258
7	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Research, 2015, 17, 43.	5.0	248
8	Survival Improvement in Patients With Medullary Thyroid Carcinoma Who Undergo Pretargeted Antiâ€“Carcinoembryonic-Antigen Radioimmunotherapy: A Collaborative Study With the French Endocrine Tumor Group. Journal of Clinical Oncology, 2006, 24, 1705-1711.	1.6	231
9	Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy for Advanced Breast Cancer: Results of Ganglion Sentinelle et ChimiothÃ©rapie Neoadjuvante, a French Prospective Multicentric Study. Journal of Clinical Oncology, 2009, 27, 726-732.	1.6	220
10	bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database: the Journal of Biological Databases and Curation, 2013, 2013, bas060-bas060.	3.0	211
11	Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival. Journal of Clinical Oncology, 2012, 30, 1949-1952.	1.6	198
12	Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. Journal of Neuro-Oncology, 2010, 97, 311-322.	2.9	169
13	Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica, 2008, 93, 471-472.	3.5	130
14	Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica, 2010, 95, 1973-1976.	3.5	124
15	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?. Blood, 2011, 117, 2009-2011.	1.4	115
16	Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkinâ€™s lymphoma: a reflection of disease infiltration or just inflammation?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1813-1821.	6.4	111
17	Long-term complications of total body irradiation in adults. International Journal of Radiation Oncology Biology Physics, 2001, 49, 125-131.	0.8	108
18	Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1487-1493.	2.1	107

#	Article	IF	Citations
19	Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment. Clinical Endocrinology, 1999, 50, 127-132.	2.4	104
20	Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du MyÃ©lome Experience. Journal of Clinical Oncology, 2013, 31, 2806-2809.	1.6	103
21	CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer. Cancer Research, 2013, 73, 6711-6721.	0.9	91
22	Surfaceâ€enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in nodeâ€negative breast cancer tumors. Proteomics, 2006, 6, 1963-1975.	2.2	89
23	Sensitivity and Prognostic Value of Positron Emission Tomography with F-18-Fluorodeoxyglucose and Sensitivity of Immunoscintigraphy in Patients with Medullary Thyroid Carcinoma Treated with Anticarcinoembryonic Antigen-Targeted Radioimmunotherapy. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4590-4597.	3.6	89
24	Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. Journal of Nuclear Medicine, 2006, 47, 247-55.	5.0	88
25	Brown fat in breast cancer patients: analysis of serial 18F-FDG PET/CT scans. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 785-791.	6.4	87
26	Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. Journal of Nuclear Medicine, 2012, 53, 1185-1192.	5.0	74
27	Interstitial brachytherapy of periorificial skin carcinomas of the face: A retrospective study of 97 cases. International Journal of Radiation Oncology Biology Physics, 2005, 63, 753-757.	0.8	73
28	Clinical and statistical evaluation of self-monitoring blood glucose meters. Diabetes Care, 1998, 21, 1919-1924.	8.6	65
29	Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. British Journal of Cancer, 2008, 98, 1993-1998.	6.4	64
30	Validation of tumorâ€associated macrophage ferritin light chain as a prognostic biomarker in nodeâ€negative breast cancer tumors: A multicentric 2004 national PHRC study. International Journal of Cancer, 2012, 131, 426-437.	5.1	64
31	Folate Supplementation Limits the Aggressiveness of Glioma via the Remethylation of DNA Repeats Element and Genes Governing Apoptosis and Proliferation. Clinical Cancer Research, 2009, 15, 3519-3529.	7.0	62
32	Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. British Journal of Cancer, 2009, 101, 166-173.	6.4	61
33	Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples. Molecular and Cellular Proteomics, 2015, 14, 2936-2946.	3.8	61
34	Post-operative care and patient satisfaction after ambulatory surgery for breast cancer patients. European Journal of Surgical Oncology, 2005, 31, 495-499.	1.0	58
35	G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis. British Journal of Cancer, 2004, 90, 189-193.	6.4	56
36	FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1029-1036.	6.4	51

#	Article	IF	Citations
37	High-Dose-Rate Brachytherapy for Nonâ€“Small-Cell Lung Carcinoma: A Retrospective Study of 226 Patients. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1112-1116.	0.8	49
38	OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. European Urology, 2021, 80, 405-414.	1.9	48
39	Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study. Annals of Surgical Oncology, 2014, 21, 3621-3627.	1.5	47
40	Genetic polymorphism at the glutathione Sâ€tranferase (GST) P1 locus is a breast cancer risk modifier. International Journal of Cancer, 2001, 91, 334-339.	5.1	45
41	Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer. British Journal of Surgery, 2006, 93, 820-824.	0.3	45
42	Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica, 2008, 93, 390-397.	3.5	45
43	Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience. Leukemia, 2012, 26, 158-159.	7.2	44
44	OLIGOPELVIS â€“ GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer. BMC Cancer, 2015, 15, 646.	2.6	44
45	Videotaped simulated interviews to improve medical students' skills in disclosing a diagnosis of cancer. Psycho-Oncology, 2010, 19, 975-981.	2.3	43
46	Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer. Supportive Care in Cancer, 2018, 26, 81-89.	2.2	43
47	Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1270-1278.	6.4	42
48	The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). BMJ Open, 2019, 9, e023568.	1.9	42
49	Learning curve for the detection of axillary sentinel lymph node in breast cancer. European Journal of Surgical Oncology, 2003, 29, 426-433.	1.0	40
50	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. Cancer Medicine, 2018, 7, 4023-4035.	2.8	39
51	c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Molecular Cancer, 2011, 10, 110.	19.2	38
52	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clinical Cancer Research, 2016, 22, 4350-4355.	7.0	38
53	High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 834, 170-177.	2.3	36
54	Osteoclasts support the survival of human plasma cells in vitro. International Immunology, 2008, 20, 775-782.	4.0	36

#	Article	IF	Citations
55	Molecular characterization of the response to chemotherapy in conventional osteosarcomas: Predictive value of HSD17B10 and IFITM2. International Journal of Cancer, 2009, 125, 851-860.	5.1	36
56	No Impairment of Quality of Life 18 Months After High-Dose Intensity-Modulated Radiotherapy for Localized Prostate Cancer: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1053-1059.	0.8	36
57	Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07). International Journal of Radiation Oncology Biology Physics, 2019, 103, 1061-1067.	0.8	36
58	Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Research and Treatment, 2008, 109, 491-501.	2.5	34
59	Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial. Lancet Haematology,the, 2017, 4, e35-e45.	4.6	33
60	Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: A feasibility study. World Journal of Gastroenterology, 2013, 19, 3249.	3.3	31
61	Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Molecular Cancer Therapeutics, 2002, 1, 267-74.	4.1	31
62	Early Assessment of Metabolic Response by 18F-FDG PET During Concomitant Radiochemotherapy of Nonâ€“Small Cell Lung Carcinoma Is Associated With Survival. Clinical Nuclear Medicine, 2015, 40, e215-e221.	1.3	29
63	Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan. Radiotherapy and Oncology, 2016, 119, 229-235.	0.6	29
64	The Impact of Nonvisualization of Sentinel Nodes on Lymphoscintigraphy in Breast Cancer. Annals of Surgical Oncology, 2005, 12, 533-538.	1.5	28
65	Validation of axillary sentinel lymph node detection in the staging of early lobular invasive breast carcinoma. Cancer, 2004, 100, 935-941.	4.1	27
66	Prognostic factors for T1â€“T2 squamous cell carcinomas of the mobile tongue: A retrospective cohort study. Head and Neck, 2011, 33, 928-934.	2.0	27
67	Molecular screening of interleukin-6 gene promoter and influence of â^'174G/C polymorphism on breast cancer. Cytokine, 2009, 47, 214-223.	3.2	26
68	Laparoscopic Sentinel Lymph Node Versus Hyperextensive Pelvic Dissection for Staging Clinically Localized Prostate Carcinoma: A Prospective Study of 200 Patients. Journal of Nuclear Medicine, 2014, 55, 753-758.	5.0	26
69	Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 559-566.	2.5	26
70	Preliminary results of a ⁶⁸Gaâ€PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decisionâ€making. Prostate, 2019, 79, 1514-1522.	2.3	25
71	Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients. PLoS ONE, 2018, 13, e0194173.	2.5	24
72	Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma. BMC Cancer, 2014, 14, 606.	2.6	23

#	Article	IF	Citations
73	Reoxygenation during radiotherapy in intermediate-risk prostate cancer. Radiotherapy and Oncology, 2019, 133, 16-19.	0.6	23
74	Pure tubular carcinoma of the breast and sentinel lymph node biopsy: A retrospective multi-institutional study of 234 cases. European Journal of Surgical Oncology, 2013, 39, 248-254.	1.0	22
75	Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. Journal of Nuclear Medicine, 2020, 61, 1205-1211.	5.0	22
76	Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS ONE, 2017, 12, e0183841.	2.5	22
77	High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. Biomedical Applications, 2001, 762, 203-209.	1.7	20
78	Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy. PLoS ONE, 2011, 6, e21129.	2.5	20
79	Logic programming reveals alteration of key transcription factors in multiple myeloma. Scientific Reports, 2017, 7, 9257.	3.3	20
80	RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).. Journal of Clinical Oncology, 2019, 37, 1092-1092.	1.6	20
81	Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 291-299.	6.4	19
82	Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation. PLoS ONE, 2016, 11, e0164643.	2.5	18
83	High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study. International Journal of Radiation Oncology Biology Physics, 2016, 96, 840-847.	0.8	18
84	Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy. Frontiers in Medicine, 2014, 1, 54.	2.6	17
85	Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases. European Journal of Surgical Oncology, 2011, 37, 971-977.	1.0	16
86	Prospective evaluation of quality of life 54Âmonths after high-dose intensity-modulated radiotherapy for localized prostate cancer. Radiation Oncology, 2013, 8, 53.	2.7	16
87	Hypofractionated irradiation in elderly patients with breast cancer after breast conserving surgery and mastectomy : Analysis of 205 cases. Radiation Oncology, 2015, 10, 161.	2.7	16
88	Clinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up. Frontiers in Medicine, 2015, 2, 46.	2.6	16
89	Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using 18F-fluoromisonidazole PET/CT: a pilot study. Oncotarget, 2018, 9, 10005-10015.	1.8	16
90	Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity. Cancer Science, 2010, 101, 889-897.	3.9	15

#	Article	IF	Citations
91	A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Research and Treatment, 2009, 116, 509-520.	2.5	14
92	18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1501-1510.	6.4	14
93	Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue. Brachytherapy, 2015, 14, 71-76.	0.5	14
94	68Gaâ€PSMAâ€11 PETâ€CT study in prostate cancer patients with biochemical recurrence and nonâ€contributive 18Fâ€Choline PETâ€CT: Impact on therapeutic decisionâ€making and biomarker changes. Prostate, 2019, 79, 454-461.	2.3	14
95	Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer, 2011, 11, 98.	2.6	13
96	Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors. Oncotarget, 2017, 8, 77050-77060.	1.8	13
97	Margin Width Should Not Still Enforce a Systematic Surgical Re-excision in the Conservative Treatment of Early Breast Infiltrative Ductal Carcinoma. Annals of Surgical Oncology, 2013, 20, 3831-3838.	1.5	12
98	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tj ETQq0 0 0 rgBT /Overlock 10	2.3	12
99	An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.. Journal of Clinical Oncology, 2017, 35, TPS1117-TPS1117.	1.6	11
100	Higher Early Monocyte and Total Lymphocyte Counts AreÂAssociated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord BloodÂAllogeneic Stem Cell Transplantation in Adults. Biology of Blood and Marrow Transplantation, 2016, 22, 1473-1479.	2.0	9
101	Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study. Clinical Colorectal Cancer, 2016, 15, e165-e174.	2.3	9
102	DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma. Clinical Epigenetics, 2020, 12, 163.	4.1	9
103	The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability. Genome Medicine, 2021, 13, 127.	8.2	9
104	Salvage extended-field irradiation in follicular non-Hodgkinâ€™s lymphoma after failure of chemotherapy. International Journal of Radiation Oncology Biology Physics, 2000, 47, 735-738.	0.8	8
105	Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: A multicentric 2004 national PHRC study. International Journal of Oncology, 2012, 41, 92-104.	3.3	8
106	Gene-expression signature functional annotation of breast cancer tumours in function of age. BMC Medical Genomics, 2015, 8, 80.	1.5	6
107	Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with 18F-Choline PET/CT in Prostate Cancer. Frontiers in Medicine, 2015, 2, 67.	2.6	6
108	Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?. Cancers, 2020, 12, 635.	3.7	6

#	Article	IF	Citations
109	High-Resolution Whole-Genome Copy Number Profiling Identifies High-Risk and Low-Risk Patients with Mantle Cell Lymphoma, a Result of the Lyma-Genomic Project Conducted on Behalf the Lysa Group. Blood, 2016, 128, 1745-1745.	1.4	6
110	Dynamic conformal arc radiosurgery for arteriovenous malformations: Outcome and influence of clinical and dosimetrical data. Radiotherapy and Oncology, 2017, 123, 251-256.	0.6	5
111	Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A Lysa Phase II Prospective Trial. Blood, 2012, 120, 906-906.	1.4	5
112	Efficacy and safety of FOLFIRINOX in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 305-305.	1.6	5
113	Prostate cancer with oligometastatic relapse: Combining stereotactic ablative radiotherapy and durvalumab, a randomized phase II trial (POSTCARD - GETUG-P13).. Journal of Clinical Oncology, 2019, 37, TPS5088-TPS5088.	1.6	5
114	Model predicting the ypN0 status after good response to chemoradiotherapy in rectal cancer. American Journal of Surgery, 2018, 216, 438-443.	1.8	4
115	Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal Cancer. Cancers, 2020, 12, 1512.	3.7	4
116	Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. Cancers, 2021, 13, 248.	3.7	4
117	Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1849-1856.	6.4	3
118	Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. Cancers, 2020, 12, 3725.	3.7	3
119	Clinical Characteristics, Chromosomal Abnormalities and Outcomes in Very Elderly Patients with Multiple Myeloma: The IFM Experience. Blood, 2012, 120, 204-204.	1.4	3
120	An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.. Journal of Clinical Oncology, 2018, 36, TPS1112-TPS1112.	1.6	3
121	Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics. Oncologie, 2014, 16, 267-276.	0.7	2
122	Intra-abdominal recurrence from colorectal carcinoma: Differences and similarities between local and peritoneal recurrence. Surgical Oncology, 2020, 32, 23-29.	1.6	2
123	Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal).. Journal of Clinical Oncology, 2019, 37, e15027-e15027.	1.6	2
124	Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review. Cancers, 2022, 14, 172.	3.7	2
125	Lymphoscintigraphy in the Sentinel Lymph Node Technique for Breast Tumor: Value of Early and Late Images for the Learning Curve. Medical Principles and Practice, 2003, 12, 17-22.	2.4	1
126	La radio-immunothÃ©rapie prÃ©ciblÃ©e des tumeurs solidesÂ: une dÃ©marche pluridisciplinaire. Medecine Nucleaire, 2007, 31, 498-505.	0.2	1

#	Article	IF	Citations
127	Abstract P2-01-01: Sentinel node surgery after neoadjuvant chemotherapy in patient with axillary node involvement: The French GANEA 2 prospective multi-institutional trial. , 2015, , .		1
128	Low Level Of NF-Kb Activity Is Associated With Higher Response Rate To Bortezomib-Based Induction Therapy In Patients With Newly Diagnosed Multiple Myeloma. Blood, 2013, 122, 3106-3106.	1.4	1
129	Efficacy and safety of FOLFIRINOX in patients with pancreatic metastatic cancer.. Journal of Clinical Oncology, 2013, 31, 248-248.	1.6	1
130	Combined abiraterone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP.. Journal of Clinical Oncology, 2017, 35, 45-45.	1.6	1
131	Molecular Prognosis in Multiple Myeloma: The IFM Experience.. Blood, 2006, 108, 3491-3491.	1.4	1
132	FOLFIRINOX in first-line metastatic pancreatic cancer regimen (FLMPC): What profile of patients take a real advantage? Real world cohort from cancer observatory from Brittany and Pays de la Loire areas.. Journal of Clinical Oncology, 2014, 32, e15204-e15204.	1.6	1
133	Gene Expression Profiles Discriminate between Pathological Complete Response and Resistance to Neoadjuvant FEC100 in Breast Cancer. Cancer Genomics and Proteomics, 2006, 3, 89-95.	2.0	1
134	Ã‰tude de faisabilitÃ© du ganglion sentinelle dans le cancer de la prostate par cÅ“lioscopieÂ: premiers rÃ©sultats. Medecine Nucleaire, 2011, 35, 461-469.	0.2	0
135	Evaluation of predictor risk factors and calculation of a margin index for ipsilateral invasive recurrence following treatment of DCIS: A 15â€year observational study. Breast Journal, 2020, 26, 1067-1068.	1.0	0
136	Gene Expression Profiling Comparison between the Major Mature B-Cell Neoplasms and Their Normal Cellular and Anatomic Counterparts: Identification of Candidate Genes Potentially Involved in Lymphomagenesis.. Blood, 2006, 108, 2375-2375.	1.4	0
137	PD5-3-2: Prognostic value of the number of examined lymph nodes in totally resected Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S479.	1.1	0
138	In Myeloma, the Prognostic Impact of Hyperdiploidy Is Mainly Related to the Gain of Chromosome 5. Blood, 2008, 112, 632-632.	1.4	0
139	Prospective determination of long-term toxicity and quality of life (QoL) of patients with prostate cancer after intensity-modulated radiotherapy (IMRT).. Journal of Clinical Oncology, 2012, 30, 151-151.	1.6	0
140	Totally implantable venous access port: A prospective long-term study of early and late complications in adult patients with cancer.. Journal of Clinical Oncology, 2014, 32, e20635-e20635.	1.6	0
141	A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus. Blood, 2014, 124, 2057-2057.	1.4	0
142	Important Prognostic Impact of Early Monocytes Recovery after Reduced Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. Blood, 2014, 124, 5923-5923.	1.4	0
143	Abstract P2-04-07: Gene-expression molecular subtyping of immunohistochemistry-typed triple-negative breast cancer tumours. , 2015, , .		0
144	OLIGOPELVIS â€“ GETUG P07, a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer: Preplanned analysis of acute toxicity.. Journal of Clinical Oncology, 2016, 34, 173-173.	1.6	0

#	Article	IF	Citations
145	PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 667.1 TPS3622-TPS3622.	1.6	0
146	Abstract P3-08-17: Clinical factors of late recurrence of HR+ early breast cancer after completion of 5 years of aromatase inhibitor and development of a prognostic tool. A study of 1496 women of the ICO database. , 2020, , .		0
147	Abstract P1-19-19: Treatments and outcome in older versus younger women with HER2-positive metastatic breast cancer in the multicenter national observational ESME database. , 2020, , .		0